about
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome coreLigand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.Superchiral Pd3 L6 Coordination Complex and Its Reversible Structural Conversion into Pd3 L3 Cl6 Metallocycles.Comparison of UHPLC-ESI-MS and Hadamard transform atmospheric pressure ion mobility-ESI-MS for rapid profiling of isomeric flavonoids.A novel cytotoxic cerium complex: aquatrichloridobis(1,10-phenanthroline)cerium(III) (KP776). Synthesis, characterization, behavior in H2O, binding towards biomolecules, and antiproliferative activity.Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSHigh resolution ion mobility-mass spectrometry for separation and identification of isomeric lipids.KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.Bioanalytical and biophysical techniques for the elucidation of the mode of action of metal-based drugs.Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.Proteome profiling of breast cancer biopsies reveals a wound healing signature of cancer-associated fibroblasts.Response Profiling Using Shotgun Proteomics Enables Global Metallodrug Mechanisms of Action To Be Established.Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters.Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells.Profiling of the human monocytic cell secretome by quantitative label-free mass spectrometry identifies stimulus-specific cytokines and proinflammatory proteins.Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules.Multinuclear cytotoxic metallodrugs: physicochemical characterization and biological properties of novel heteronuclear gold-titanium complexes.Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA.Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes.In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands.Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiA glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes.The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques.Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.Simultaneous endo and exo Complex Formation of Pyridine[4]arene Dimers with Neutral and Anionic Guests.Highly Oxygenated Multifunctional Compounds in α-Pinene Secondary Organic Aerosol.Changes of several brain receptor complexes in the cerebral cortex of patients with Alzheimer disease: probable new potential pharmaceutical targets.The metalation of hen egg white lysozyme impacts protein stability as shown by ion mobility mass spectrometry, differential scanning calorimetry, and X-ray crystallography.Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compoundsNanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazineA calibration framework for the determination of accurate collision cross sections of polyanions using polyoxometalate standardsA novel framework for molecular characterization of atmospherically relevant organic compounds based on collision cross section and mass-to-charge ratio
P50
Q27666776-B03D50E8-007B-4546-90AC-0DB90FE73D81Q27682260-EE7F7B22-90A1-4036-BA4B-0C15E2581CCDQ31016310-46CEEAD9-B687-44CC-8980-76231EFE8165Q33461532-FA074893-14C3-4D6E-A00E-C03EC513707FQ33519607-F5178D24-505A-4290-88E6-2DF342C24880Q33640724-7B7BBDA8-7964-41E1-8459-72E914C2C05EQ34394993-61B04AB0-B655-42BF-BE6F-3AEB1A5D0080Q35756994-CAC0788F-5550-4534-AD68-780271050664Q37313183-36E10BB9-116A-4696-A1F5-9976274FE9FAQ37576021-CD1B1A59-B619-455D-87E6-7164B21B2CB0Q37951057-375521B3-9DEE-497F-A051-B09FEA7BEE8BQ38052406-BC7F7C26-F198-471A-B760-123D84654AFFQ38105454-E728CEED-6393-4301-B3CF-36745CD0233DQ38345952-82C7BAF2-90F8-4998-9CC6-3629D9DA52ADQ38954998-6D4488FB-469B-4049-9089-1E1147F8657DQ39029609-DDBAE775-FC2E-4943-B42B-A53B2DFE1535Q39178846-BEEFAD95-8B56-4AA4-8082-1FE5E703F98BQ39270897-5F53F89B-2D01-400E-A81F-AC8A2CEA4BEAQ39307534-20A807EE-D37F-40FF-9506-560A4427DB27Q39457114-ED93E333-266F-471C-8EBE-E9A5948BBC83Q39482812-29328BE8-9B5C-4D8B-8B7A-E4948D1993A8Q39576903-12D19B6B-BABF-4EAC-B69F-BE5C09BAF58CQ39582316-0200D03A-867D-45C0-9869-74700C86879BQ39623416-522317D1-7980-45B2-BFB1-C85DC78A7DEFQ39952629-0CC515E0-023E-4129-BA4D-DBAD66A249EDQ40086077-6F5E103D-FA57-49B1-9B5E-532195D5183AQ40150994-62C8D641-630D-4713-AEAB-C03C68A958B5Q40162812-2046F753-6D62-40D9-878A-D5D3C5F23C0CQ41770357-EA5EFBB1-C9F0-4CBD-9EE3-7376A1779F1FQ45924256-817A7A58-387B-43FD-8213-091008D7B161Q46409766-3257CEA6-2BD5-4B49-8256-0432F01866CFQ46789743-C5384009-D0E5-4C31-BF0A-28BDCF57E0A8Q48194422-46CD8A96-53DF-4370-B4EB-D1771EB3C341Q48229858-D98928FF-A4E8-4F0E-AAB9-8BE40A745D3AQ48831624-7308EC9D-CBF2-439E-8F1C-534FF41D56DCQ51080178-FDCAD347-45EB-45DA-9998-7478F70A3A5DQ57184388-F51B7576-E08D-449D-BF48-B18E43582D55Q57305774-932B0A5E-BAD6-45F1-A47B-C11F5E97850FQ57465977-592FE311-EB8A-4E67-B007-35EE695E8DD0Q57880782-32FF1452-142C-4C5C-ADCB-67788F61A232
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Groessl
@ast
Michael Groessl
@en
Michael Groessl
@es
Michael Groessl
@nl
Michael Groessl
@sl
type
label
Michael Groessl
@ast
Michael Groessl
@en
Michael Groessl
@es
Michael Groessl
@nl
Michael Groessl
@sl
prefLabel
Michael Groessl
@ast
Michael Groessl
@en
Michael Groessl
@es
Michael Groessl
@nl
Michael Groessl
@sl
P106
P1153
23469265500
P21
P31
P496
0000-0002-6740-5980